Talazoparib

Generic Name: Talazoparib

Brand Names: Talzenna

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₄F_₂N_₆O

CAS Number: 1207456-01-6

Unique Ingredient Identifier: 9QHX048FRV

Background: Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...

Indication: Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...

Associated Conditions: HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)

Associated Therapies: -

Clinical Trials

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

Phase 2

Terminated

Conditions: Triple Negative Breast Cancer

Interventions: Drug: ZEN003694
Drug: Talazoparib

First Posted Date: 2019-04-03

Last Posted Date: 2024-05-03

Lead Sponsor: Zenith Epigenetics

Target Recruit Count: 115

Registration Number: NCT03901469

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson, Houston, Texas, United States

and more 16 locations

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1

Terminated

Conditions: RCC
Colorectal Cancer
Solid Tumor
TNBC - Triple-Negative Breast Cancer
CRC
ccRCC
Clear Cell Renal Cell Carcinoma

Interventions: Drug: CB-839
Drug: Talazoparib

First Posted Date: 2019-03-14

Last Posted Date: 2022-02-17

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 33

Registration Number: NCT03875313

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 6 locations

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma
Refractory Extensive Stage Small Cell Lung Carcinoma

Interventions: Drug: Talazoparib
Drug: Temozolomide

First Posted Date: 2018-09-14

Last Posted Date: 2024-11-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT03672773

Locations: 🇺🇸
Ft. Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States

and more 3 locations

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Avelumab
Drug: Talazoparib
Drug: Binimetinib

First Posted Date: 2018-08-20

Last Posted Date: 2022-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03637491

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States
🇺🇸
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 13 locations

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2

Terminated

Conditions: Genes, BRCA 1
Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: Avelumab
Drug: Talazoparib

First Posted Date: 2018-06-21

Last Posted Date: 2023-09-25

Lead Sponsor: Pfizer

Target Recruit Count: 202

Registration Number: NCT03565991

Locations: 🇺🇸
Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States
🇺🇸
Northside Hospital, Inc. - GCS/Northside, Atlanta, Georgia, United States
🇺🇸
Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States

and more 83 locations

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2

Terminated

Conditions: Early Breast Cancer

Interventions: Drug: TALAZOPARIB

First Posted Date: 2018-04-17

Last Posted Date: 2021-11-09

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT03499353

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Thornton, Colorado, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 65 locations

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2

Completed

Conditions: BARD1 Gene Mutation
FANCM Gene Mutation
Recurrent Squamous Cell Lung Carcinoma
ATR Gene Mutation
BRCA2 Gene Mutation
FANCC Gene Mutation
FANCF Gene Mutation
RAD54L Gene Mutation
CHEK2 Gene Mutation
FANCD2 Gene Mutation

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Talazoparib

First Posted Date: 2017-12-19

Last Posted Date: 2021-06-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 51

Registration Number: NCT03377556

Locations: 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸
Mercy Hospital Joplin, Joplin, Missouri, United States

and more 1149 locations

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Breast Neoplasms

Interventions: Drug: talazoparib

First Posted Date: 2017-11-17

Last Posted Date: 2024-08-22

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT03343054

Locations: 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
🇯🇵
National Hospital Organization Osaka National Hospital, Osaka, Japan

and more 5 locations

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Talazoparib

First Posted Date: 2017-05-11

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT03148795

Locations: 🇫🇷
Institut de Cancerologie Strasbourg Europe, Strasbourg, France
🇺🇸
Levine Cancer Institute-Lincolnton, Lincolnton, North Carolina, United States
🇦🇺
Intergrated Clinical Oncology Network (ICON), South Brisbane, Queensland, Australia

and more 115 locations

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Talazoparib
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2017-03-13

Last Posted Date: 2021-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03077607

Locations: 🇲🇩
ARENSIA Exploratory Medicine Phase I Unit, PMSI Institute of Oncology, Chisinau, Moldova, Republic of
🇷🇺
"BioEq" LLC, Saint-Petersburg, Russian Federation
🇷🇺
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy